Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

NMDP BioTherapies and the NMDP BioTherapies Cord Blood Bank Alliance Introduce Optimal Cord Blood Units for Manufacture of NK Cell Therapies And Other Cord Derived Cell Therapies

August 2, 2024 By Cade Hildreth, Founder & President Leave a Comment

Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells

MINNEAPOLIS, July 18, 2024 — NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the NMDP BioTherapies Cord Blood Bank Alliance (CBBA), a partnership between NMDP BioTherapies and nine public cord blood banks, are making available pre-identified cord blood units that are optimized for manufacture of cord-derived cell therapies, and in particular cord-derived NK cell therapies. The identification and supply of these units leverages the over 200,000 cord blood units in the inventory of the CBBA as well as NMDP BioTherapies’ cord unit search platform, through which individual cord blood units that meet specific requirements can be rapidly identified. [Read more…]

Astellas, Universal Cells, and Osaka University to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy

August 1, 2024 By Cade Hildreth, Founder & President Leave a Comment

Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas’ Universal Donor Cell Technology.

TOKYO and OSAKA, Japan, July 22, 2024 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) and Graduate School of Medicine / Faculty of Medicine, Osaka University (President: Shojiro Nishio) announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas, “AIRM”), Universal Cells (a wholly owned subsidiary of Astellas) and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell*¹-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease*². [Read more…]

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics

July 25, 2024 By Cade Hildreth, Founder & President Leave a Comment

First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021

Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults

IND filing for OpCT-001 is planned for 2024

[Read more…]

INCELL Pioneering the World’s First Effective Cell Therapy for ALS

July 24, 2024 By Cade Hildreth, Founder & President 1 Comment

San Antonio, Texas, July 25, 2024 – ALS, or amyotrophic lateral sclerosis, is defined by the ALS Association (als.org) as a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS symptoms vary and patients may lose the ability to speak, eat, move and breathe. There is no cure. The Mayo Clinic reports (mayoclinic.org) that no treatments can reverse ALS damage, but they may slow the progression of disease symptoms or help prevent complications. INCELL is committed to tackling innovative ALS therapy. [Read more…]

iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson’s Disease

July 23, 2024 By Cade Hildreth, Founder & President Leave a Comment

WUHAN, China, June 24, 2024 — On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson’s Disease. This marks a significant milestone as NouvNeu001 becomes the world’s first chemically induced allogeneic cell therapy product to enter clinical stages for Parkinson’s disease in the US. Previously, the “Combined Phase I/II Clinical Study” of NouvNeu001 had already received approval from China NMPA in August 2023 and demonstrated positive safety and efficacy data in its Phase I trials. On June 20, 2024, iRegene further announced IND approval of NouvNeu001 by the U.S. FDA for the treatment of mid-to-late stage of Parkinson’s disease. [Read more…]